Depleting chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance
Life Science Alliance · 2025
DOI: 10.26508/lsa.202402870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Karolina Borankova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Mitochondrial Dynamics, Dynamins, Drug Resistance, Neoplasm, Sarcoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grantová Agentura České Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy.
Abstract (Originalsprache)
Specific patterns of mitochondrial dynamics have been repeatedly reported to promote drug resistance in cancer. However, whether targeting mitochondrial fission– and fusion–related proteins could be leveraged to combat multidrug-resistant pediatric sarcomas is poorly understood. Here, we demonstrated that the expression and activation of the mitochondrial fission mediator DRP1 are affected by chemotherapy exposure in common pediatric sarcomas, namely, rhabdomyosarcoma and osteosarcoma. Unexpectedly, decreasing DRP1 activity through stable DRP1 knockdown neither attenuated sarcoma drug resistance nor affected growth rate or mitochondrial network morphology. The minimal impact on sarcoma cell physiology, along with the up-regulation of fission adaptor proteins (MFF and FIS1) detected in rhabdomyosarcoma cells, suggests an alternative DRP1-independent mitochondrial fission mechanism that may efficiently compensate for the lack of DRP1 activity. By exploring the upstream mitophagy and mitochondrial fission regulator, AMPKα1, we found that markedly reduced AMPKα1 levels are sufficient to maintain AMPK signaling capacity without affecting chemosensitivity. Collectively, our findings challenge the direct involvement of DRP1 in pediatric sarcoma drug resistance and highlight the complexity of yet-to-be-characterized noncanonical regulators of mitochondrial dynamics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
- Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic jan.skoda@sci.muni.cz.
ORCID-Profile: Karolina Borankova, Maria Krchniakova, Jan Skoda
Förderung
- Grantová Agentura České Republiky
- Ministerstvo Školství, Mládeže a Tělovýchovy
Zitieren
APA
Borankova, K., Solny, M., Krchniakova, M., & Skoda, J. (2025). Depleting chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance. Life Science Alliance. https://doi.org/10.26508/lsa.202402870
Vancouver
Borankova K, Solny M, Krchniakova M, Skoda J. Depleting chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance. Life Science Alliance. 2025. doi:10.26508/lsa.202402870
BibTeX
@article{Borankova2025,
author = {Borankova, Karolina and Solny, Matyas and Krchniakova, Maria and Skoda, Jan},
title = {Depleting chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance},
journal = {Life Science Alliance},
year = {2025},
doi = {10.26508/lsa.202402870}
}
EUVIMED